D. Boral Capital Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA)

Key Points

• D. Boral Capital has reaffirmed its "buy" rating for Humacyte (NASDAQ:HUMA), with a price objective of $25.00 per share.
• Currently, Humacyte has a consensus rating of "Moderate Buy" among analysts, with a target price averaging around $11.71.
• Humacyte's stock recently traded at $1.74, showing significant volatility in trading volume with over 16 million shares exchanged.

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reissued by research analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock.

HUMA has been the subject of several other reports. Benchmark decreased their price objective on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Wall Street Zen raised shares of Humacyte from a "sell" rating to a "hold" rating in a report on Saturday. Finally, HC Wainwright assumed coverage on shares of Humacyte in a research note on Wednesday, May 14th. They set a "buy" rating and a $4.00 target price for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Humacyte presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.71.

Humacyte Stock Performance

Humacyte stock traded down $0.75 during midday trading on Monday, hitting $1.74. 16,707,169 shares of the company's stock were exchanged, compared to its average volume of 3,882,617. Humacyte has a 12-month low of $1.15 and a 12-month high of $7.73. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68. The stock has a market cap of $269.13 million, a price-to-earnings ratio of -2.53 and a beta of 1.90. The firm's 50 day simple moving average is $2.40 and its 200 day simple moving average is $2.53.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.94 million. Equities research analysts predict that Humacyte will post -1.27 EPS for the current year.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. Heights Capital Management Inc. acquired a new stake in shares of Humacyte in the 1st quarter valued at $6,863,000. RA Capital Management L.P. bought a new position in shares of Humacyte in the first quarter valued at about $5,648,000. Woodline Partners LP raised its holdings in Humacyte by 235.7% during the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock worth $14,386,000 after purchasing an additional 2,000,268 shares during the last quarter. Monashee Investment Management LLC bought a new stake in Humacyte during the 1st quarter worth about $3,410,000. Finally, Maven Securities LTD bought a new stake in Humacyte during the 1st quarter worth about $1,790,000. Institutional investors and hedge funds own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.